The mTOR inhibitor everolimus has been recently approved for the treatment of advanced ER+ breast cancer [7], and several trials are currently evaluating the efficacy of mTOR inhibitors in the TNBC subtype [27]. This evidence concerns the gene MTOR and breast carcinoma.